Like pls_老虎社区_美港股上老虎

2021-10-12

Like pls

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德 (Cathie Wood) 大幅跳水：她刚刚购买的 3 只下跌股票</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":826501473,"tweetId":"826501473","gmtCreate":1634032518783,"gmtModify":1634032519027,"author":{"id":3586424409701165,"idStr":"3586424409701165","authorId":3586424409701165,"authorIdStr":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":40,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Like pls</body></html>","htmlText":"<html><head></head><body>Like pls</body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/826501473","repostId":1105330036,"repostType":4,"repost":{"id":"1105330036","kind":"news","pubTimestamp":1634032364,"share":"https://www.laohu8.com/m/news/1105330036?lang=zh_CN&edition=full","pubTime":"2021-10-12 17:52","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德 (Cathie Wood) 大幅跳水：她刚刚购买的 3 只下跌股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330036","media":"Motley Fool","summary":"All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.","content":"Key Points<blockquote>要点</blockquote> <ul> <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li> <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li> <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li> </ul> <blockquote><ul><li>伍德最近买入了陷入困境的合成生物学股票 Ginkgo Bioworks 的股票，此前一份卖空报告将其推低。</li><li>ARK Invest ETF 还增加了一家名为 Signify Health 的医疗保健中间商的股票。</li><li>Beam Therapeutics 是一家比基因编辑更安全的生物技术公司，上周每天也进入了 ARK Innovation ETF。</li></ul></blockquote> Do you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.<blockquote>你知道当股市击败他们最喜欢的股票时，自信的投资者会做什么吗？他们利用便宜的价格，买更多。</blockquote> Last week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.<blockquote>上周对于少数生命科学和医疗保健股票来说是糟糕的一周。但这并没有阻止 ARK Invest 创始人兼首席执行官凯西·伍德 (Cathie Wood) 增持一些她最喜欢的股票头寸。</blockquote> Here's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).<blockquote>这就是伍德最近购买更多股票的原因银杏生物工厂（纽约证券交易所代码：DNA），表示健康（纽约证券交易所代码：SGFY），以及射束治疗（纳斯达克股票代码：BEAM）</blockquote> <img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Ginkgo Bioworks<blockquote>1. 银杏生物工厂</blockquote> Wood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.<blockquote>早在一家特殊目的收购公司于 9 月中旬将这家合成生物学公司上市之前，伍德就一直是这家合成生物学公司的忠实粉丝。上周，Wood 多次增加 Ark Invests 银杏生物工厂的头寸，尽管该股面临很大压力。</blockquote> A lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.<blockquote>最近，一位卖空者的长篇抨击凸显了该公司缺乏盈利能力，并重创了该股。Ginkgo Bioworks正在建立一个平台，该平台将使各种企业能够随意编程活细胞。不幸的是，对此类服务的需求远没有 Gingko Bioworks 投资者希望的那么强劲。</blockquote> Ginkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.<blockquote>Ginkgo Bioworks正试图通过投资初创企业来解决合成生物学服务需求疲软的问题。不过，该公司并没有交付现金，而是发放了企业只能用来支付代工服务费用的银杏币。</blockquote> Years ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.<blockquote>多年前，全球领先的合成生物学公司，阿米里斯（纳斯达克股票代码：AMRS），意识到不能依赖第三方满足需求。不过，由于在健康和美容领域销售自己的品牌，Amyris终于开始产生可持续的利润。</blockquote> Gingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.<blockquote>Gingko Bioworks 不会是第一家痛苦地认识到代工服务利润不高的合成生物学公司。这是因为设计一种能够产生特定成分的生物体是这项业务中最容易的部分。然而，银杏生物工厂尚未应对的大规模生产使此类冒险变得值得。</blockquote> <img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 2. Signify Health<blockquote>2.表示健康</blockquote> This relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.<blockquote>这只相对较新的医疗保健股票自 2 月份上市后不久达到峰值以来已下跌约 54%。不过，木头不会摇晃。Ark Invest funds 上周每天都购买更多 Signify Health 股票。</blockquote> Signify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.<blockquote>Signify Health 是一家与医疗保健提供者和医疗保健福利经理合作的中间商，例如国歌保持较低的平均成本。Signify Health目前最受欢迎的服务包括对患者进行家庭评估，以减少再次入院。</blockquote> Ever since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.<blockquote>自2010年患者保护与平价医疗法案通过以来，医疗保健提供者越来越有可能获得特定健康事件的固定费率，如白内障摘除手术或膝关节置换。通过让患者尽可能长时间地呆在家里，Signify Health可以为保险公司节省一大笔钱。</blockquote> Signify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.<blockquote>Signify Health的医疗保健支出管理方法对Signify及其客户来说效果良好。2021年上半年，该公司公布调整后的息税折旧摊销前利润（EBITDA）达到令人印象深刻的8900万美元。</blockquote> <img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 3. Beam Therapeutics<blockquote>3.射束疗法</blockquote> This biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.<blockquote>这只生物技术股票于 2020 年初首次上市，成为该榜单上历史最悠久的股票。不过，自 7 月份达到峰值以来，它的价值已经损失了约 37%。伍德并没有被最近的下滑吓倒，他将 Beam Therapeutics 的股票添加到了方舟创新ETF（NYSEMKT:ARKK）上周的每一天。</blockquote> Wood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.<blockquote>伍德对这家公司的基础编辑技术感兴趣。大多数基因编辑技术涉及在特定位点切割DNA链，以移除或插入核苷酸序列。不幸的是，这种方法伴随着很多风险。Beam Therapeutics 采用碱基编辑技术，可以将胸腺嘧啶转化为腺嘌呤或胞嘧啶转化为鸟嘌呤。</blockquote> Beam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.<blockquote>Beam Therapeutics 的方法应该比断裂和修复 DNA 链的问题要少得多。对更安全的基因编辑方法的需求也在上升。破坏 DNA 的实验性基因疗法带来的一系列安全隐患，包括异体最近的内爆表明，迫切需要一种更好的基因编辑方法。</blockquote> Beam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.<blockquote>Beam Therapeutics、Signify Health 和 Ginkgo Bioworks 本月初进入了 Wood 的购买清单。让我们看看随着10月份的进展，她是否会继续增加这些职位。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德 (Cathie Wood) 大幅跳水：她刚刚购买的 3 只下跌股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought<blockquote>凯西·伍德 (Cathie Wood) 大幅跳水：她刚刚购买的 3 只下跌股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-10-12 17:52\n\n</h4>\n</header>\n<article>\nKey Points<blockquote>要点</blockquote> <ul> <li>Wood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.</li> <li>ARK Invest ETFs also added shares of a healthcare middleman called Signify Health.</li> <li>Beam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.</li> </ul> <blockquote><ul><li>伍德最近买入了陷入困境的合成生物学股票 Ginkgo Bioworks 的股票，此前一份卖空报告将其推低。</li><li>ARK Invest ETF 还增加了一家名为 Signify Health 的医疗保健中间商的股票。</li><li>Beam Therapeutics 是一家比基因编辑更安全的生物技术公司，上周每天也进入了 ARK Innovation ETF。</li></ul></blockquote> Do you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.<blockquote>你知道当股市击败他们最喜欢的股票时，自信的投资者会做什么吗？他们利用便宜的价格，买更多。</blockquote> Last week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.<blockquote>上周对于少数生命科学和医疗保健股票来说是糟糕的一周。但这并没有阻止 ARK Invest 创始人兼首席执行官凯西·伍德 (Cathie Wood) 增持一些她最喜欢的股票头寸。</blockquote> Here's why Wood recently bought more shares of&nbsp;Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and&nbsp;Beam Therapeutics(NASDAQ:BEAM).<blockquote>这就是伍德最近购买更多股票的原因银杏生物工厂（纽约证券交易所代码：DNA），表示健康（纽约证券交易所代码：SGFY），以及射束治疗（纳斯达克股票代码：BEAM）</blockquote> <img src=\"https://static.tigerbbs.com/02dd7addbf203fd4a490b6e8965ddcaf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Ginkgo Bioworks<blockquote>1. 银杏生物工厂</blockquote> Wood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.<blockquote>早在一家特殊目的收购公司于 9 月中旬将这家合成生物学公司上市之前，伍德就一直是这家合成生物学公司的忠实粉丝。上周，Wood 多次增加 Ark Invests 银杏生物工厂的头寸，尽管该股面临很大压力。</blockquote> A lengthy diatribe from a short seller recently highlighted the company's lack of profitability and&nbsp;battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.<blockquote>最近，一位卖空者的长篇抨击凸显了该公司缺乏盈利能力，并重创了该股。Ginkgo Bioworks正在建立一个平台，该平台将使各种企业能够随意编程活细胞。不幸的是，对此类服务的需求远没有 Gingko Bioworks 投资者希望的那么强劲。</blockquote> Ginkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.<blockquote>Ginkgo Bioworks正试图通过投资初创企业来解决合成生物学服务需求疲软的问题。不过，该公司并没有交付现金，而是发放了企业只能用来支付代工服务费用的银杏币。</blockquote> Years ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally&nbsp;beginning to produce a sustainable profit.<blockquote>多年前，全球领先的合成生物学公司，阿米里斯（纳斯达克股票代码：AMRS），意识到不能依赖第三方满足需求。不过，由于在健康和美容领域销售自己的品牌，Amyris终于开始产生可持续的利润。</blockquote> Gingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.<blockquote>Gingko Bioworks 不会是第一家痛苦地认识到代工服务利润不高的合成生物学公司。这是因为设计一种能够产生特定成分的生物体是这项业务中最容易的部分。然而，银杏生物工厂尚未应对的大规模生产使此类冒险变得值得。</blockquote> <img src=\"https://static.tigerbbs.com/de8d295959ca896c41dc326db1d99cb1\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 2. Signify Health<blockquote>2.表示健康</blockquote> This relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.<blockquote>这只相对较新的医疗保健股票自 2 月份上市后不久达到峰值以来已下跌约 54%。不过，木头不会摇晃。Ark Invest funds 上周每天都购买更多 Signify Health 股票。</blockquote> Signify Health is a middleman that works with healthcare providers and healthcare benefits managers such as&nbsp;Anthem&nbsp;to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.<blockquote>Signify Health 是一家与医疗保健提供者和医疗保健福利经理合作的中间商，例如国歌保持较低的平均成本。Signify Health目前最受欢迎的服务包括对患者进行家庭评估，以减少再次入院。</blockquote> Ever since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.<blockquote>自2010年患者保护与平价医疗法案通过以来，医疗保健提供者越来越有可能获得特定健康事件的固定费率，如白内障摘除手术或膝关节置换。通过让患者尽可能长时间地呆在家里，Signify Health可以为保险公司节省一大笔钱。</blockquote> Signify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported&nbsp;adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.<blockquote>Signify Health的医疗保健支出管理方法对Signify及其客户来说效果良好。2021年上半年，该公司公布调整后的息税折旧摊销前利润（EBITDA）达到令人印象深刻的8900万美元。</blockquote> <img src=\"https://static.tigerbbs.com/eb640d018fc66df3bcf9229a3c46bae8\" tg-width=\"2000\" tg-height=\"1581\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 3. Beam Therapeutics<blockquote>3.射束疗法</blockquote> This biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value.&nbsp;Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the&nbsp;Ark Innovation ETF(NYSEMKT:ARKK)&nbsp;every day last week.<blockquote>这只生物技术股票于 2020 年初首次上市，成为该榜单上历史最悠久的股票。不过，自 7 月份达到峰值以来，它的价值已经损失了约 37%。伍德并没有被最近的下滑吓倒，他将 Beam Therapeutics 的股票添加到了方舟创新ETF（NYSEMKT:ARKK）上周的每一天。</blockquote> Wood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs&nbsp;a base-editing technique&nbsp;that can convert thymine to adenine or cytosine to guanine.<blockquote>伍德对这家公司的基础编辑技术感兴趣。大多数基因编辑技术涉及在特定位点切割DNA链，以移除或插入核苷酸序列。不幸的是，这种方法伴随着很多风险。Beam Therapeutics 采用碱基编辑技术，可以将胸腺嘧啶转化为腺嘌呤或胞嘧啶转化为鸟嘌呤。</blockquote> Beam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer&nbsp;gene-editing&nbsp;method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including&nbsp;Allogene's&nbsp;recent implosion, make it clear that a better way to edit genes is sorely needed.<blockquote>Beam Therapeutics 的方法应该比断裂和修复 DNA 链的问题要少得多。对更安全的基因编辑方法的需求也在上升。破坏 DNA 的实验性基因疗法带来的一系列安全隐患，包括异体最近的内爆表明，迫切需要一种更好的基因编辑方法。</blockquote> Beam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.<blockquote>Beam Therapeutics、Signify Health 和 Ginkgo Bioworks 本月初进入了 Wood 的购买清单。让我们看看随着10月份的进展，她是否会继续增加这些职位。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","ARKK":"ARK Innovation ETF","DNA":"Ginkgo Bioworks Holdings Inc.","SGFY":"Signify Health, Inc."},"source_url":"https://www.fool.com/investing/2021/10/12/cathie-wood-goes-dumpster-diving-3-sagging-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105330036","content_text":"Key Points\n\nWood recently bought shares of embattled synthetic biology stock Ginkgo Bioworks after a short-seller report pushed it lower.\nARK Invest ETFs also added shares of a healthcare middleman called Signify Health.\nBeam Therapeutics, a biotech with a safer alternative to gene editing, also made its way into the ARK Innovation ETF every day last week.\n\n\nDo you know what confident investors do when the stock market thrashes their favorite stocks? They take advantage of the bargain pricing and buy a lot more.\nLast week was a lousy one for a handful of life science and healthcare stocks. That didn't stop Cathie Wood, founder and CEO of ARK Invest, from adding to some of her favorite stock positions.\nHere's why Wood recently bought more shares of Ginkgo Bioworks(NYSE:DNA),Signify Health(NYSE:SGFY), and Beam Therapeutics(NASDAQ:BEAM).\nIMAGE SOURCE: GETTY IMAGES.\n1. Ginkgo Bioworks\nWood was a big fan of this synthetic biology company long before a special purpose acquisition company took it public in mid-September. Several times last week, Wood increased Ark Invests' Ginkgo Bioworks position even though the stock is under a lot of pressure.\nA lengthy diatribe from a short seller recently highlighted the company's lack of profitability and battered the stock. Ginkgo Bioworks is building a platform that should enable a variety of businesses to program living cells at will. Unfortunately, demand for such services isn't nearly as strong as Gingko Bioworks' investors would like it to be.\nGinkgo Bioworks is trying to solve the problem of weak demand for synthetic biology services by investing in start-ups. Instead of handing over cash, though, the company's been giving out Gingko-bucks that businesses can only use to pay for foundry services.\nYears ago, the world's leading synthetic biology company,Amyris(NASDAQ:AMRS), realized it can't rely on third parties for demand. Thanks to sales of its own brands in the health and beauty space, though, Amyris is finally beginning to produce a sustainable profit.\nGingko Bioworks wouldn't be the first synthetic biology company to learn the hard way that foundry services aren't very profitable. That's because engineering an organism that can produce a specific ingredient is the easy part of this business. Production at a scale that makes such ventures worthwhile, though, is a challenge that Gingko Bioworks hasn't addressed yet.\nIMAGE SOURCE: GETTY IMAGES.\n2. Signify Health\nThis relatively new healthcare stock has tumbled around 54% since peaking shortly after its stock market debut in February. Wood isn't shaken, though. Ark Invest funds bought more shares of Signify Health every day last week.\nSignify Health is a middleman that works with healthcare providers and healthcare benefits managers such as Anthem to keep average costs low. Signify Health's most popular service at the moment involves in-home evaluations of patients in an attempt to reduce hospital readmissions.\nEver since the passage of the Affordable Care Act in 2010, healthcare providers are increasingly likely to receive fixed rates for specific health episodes like cataract-removal surgery or knee replacement. By keeping patients at home as much as is safely manageable, Signify Health can save insurers a bundle.\nSignify Health's approach to healthcare spending management is working out well for Signify and its clients. In the first half of 2021, the company reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached an impressive $89 million.\nIMAGE SOURCE: GETTY IMAGES.\n3. Beam Therapeutics\nThis biotech stock made its market debut in early 2020, making it the oldest stock on this list. Since peaking in July, though, it's lost around 37% of its value. Undaunted by the recent slide, Wood added shares of Beam Therapeutics to the Ark Innovation ETF(NYSEMKT:ARKK) every day last week.\nWood is interested in this company's base editing technology. Most gene-editing techniques involve cutting a DNA strand at a specific site to remove or insert a sequence of nucleotides. Unfortunately, this method comes with a lot of risks. Beam Therapeutics employs a base-editing technique that can convert thymine to adenine or cytosine to guanine.\nBeam Therapeutics' approach should be a lot less problematic than breaking and repairing DNA strands. Demand for a safer gene-editing method is on the rise too. A string of safety scares from experimental gene therapies that break DNA, including Allogene's recent implosion, make it clear that a better way to edit genes is sorely needed.\nBeam Therapeutics, Signify Health, and Ginkgo Bioworks made it onto Wood's buy list early this month. Let's see if she keeps adding to these positions as October progresses.","news_type":1,"symbols_score_info":{"BEAM":0.9,"DNA":0.9,"SGFY":0.9,"ARKK":0.9}},"isVote":1,"tweetType":1,"viewCount":892,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/826501473"}